← Back to Search
Neurodegenerative Dementia And Parkinsonism
A. Gabelle, F. Portet, C. Berr, J. Touchon
Published 2010 · Medicine
Download PDFAnalyze on Scholarcy
BackgroundDementia and Parkinsonism are two major neurodegenerative disorders. Accurate diagnosis can be difficult when patients have both syndromes because of a wide range of etiologies.ObjectivesTo improve clinical diagnosis, we propose a disease classification based on the pathological proteins which are involved in the neuropathological disease process.DesignFour neuropathological classes are proposed based on four major proteins, tau, Aβ, α-synuclein and TDP43: 1/ Tauopathy and amyloidopathy with possible Parkinsonism, 2/ Tauopathy with predominant Parkinsonism, 3/ Synucleinopathies with cognitive impairment/dementia and 4/ The TAR DNA binding protein 43 (TDP-43). This classification raises certain questions in clinical practice due to intriguing overlaps between clinical presentations despite the same pathological protein being involved.ConclusionThe development of molecular and pathological protein research in neurodegenerative disorders can help classify the clinical association of dementia and Parkinsonism and improve therapeutic strategies against proteins involved in the degenerative process.
This paper references
Extrapyramidal features in advanced Down's syndrome: clinical evaluation and family history.
P. Vieregge (1991)
Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration.
J. Gass (2006)
Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study.
B. Boeve (2006)
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination
G. Wenning (1998)
Extrapyramidal symptoms and signs in Alzheimer's disease: Pravalence and correlation with the first symptom
M. Tsolaki (2001)
Pattern of Tau forms in CSF is altered in progressive supranuclear palsy
B. Borroni (2009)
A systematic review of prevalence studies of dementia in Parkinson's disease
D. Aarsland (2005)
Phosphorylated tau: toxic, protective, or none of the above.
R. Castellani (2008)
Frontotemporal Dementia with Tau Pathology
L. Gasparini (2007)
A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.
R. Stern (1994)
Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older
T. Rahkonen (2003)
Nuclear factor TDP-43 binds to the polymorphic TG repeats in CFTR intron 8 and causes skipping of exon 9: a functional link with disease penetrance.
E. Buratti (2004)
Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction.
M. Rowan (2007)
Protein Aggregation Mechanisms in Synucleinopathies: Commonalities and Differences
K. Beyer (2007)
Motor impairment in PD
G. Levy (2000)
Ubiquitination of α-synuclein and autophagy in Parkinson's disease
S. Engelender (2008)
Familial frontotemporal dementia with ubiquitin-positive, tau-negative inclusions
A. Kertesz (2000)
Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival
P. van Damme (2008)
[Fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17): clinical criteria].
Z. Wszolek (2003)
Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis
Z. He (2003)
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
J. Hardy (2002)
Imaging of corticobasal degeneration syndrome
M. Koyama (2007)
Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia.
J. Snowden (2006)
Prominent phenotypic variability associated with mutations in Progranulin
B. Kelley (2009)
HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin‐positive, tau‐negative inclusions caused by a missense mutation in the signal peptide of progranulin
O. Mukherjee (2006)
Progranulin in frontotemporal lobar degeneration and neuroinflammation
Z. Ahmed (2007)
Do extrapyramidal features in Alzheimer patients treated with acetylcholinesterase inhibitors predict disease progression?
H. Brodaty (2007)
“Applause sign” helps to discriminate PSP from FTD and PD
B. Dubois (2005)
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative
R. Rademakers (2007)
Asymmetrical alien hands in corticobasal degeneration
D. B. Fitzgerald (2007)
Extrapyramidalism in Alzheimer's disease: prevalence, psychiatric, and neuropsychological correlates.
M. Merello (1994)
alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease.
Kohichi Kawahara (2008)
The last tangle of tau.
Huiping Ding (2008)
Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.
C. Williams-Gray (2007)
Progranulin: normal function and role in neurodegeneration
Jason L. Eriksen (2008)
Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations.
J. Whitwell (2007)
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.
M. Martinez-Vicente (2008)
Measuring brain stem and cerebellar damage in parkinsonian syndromes using diffusion tensor MRI
C. Blain (2006)
White matter changes in corticobasal degeneration syndrome and correlation with limb apraxia.
B. Borroni (2008)
Voxel-based morphometry in autopsy proven PSP and CBD
K. Josephs (2008)
Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia
J. Van der Zee (2007)
The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene.
I. Mackenzie (2006)
Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease.
G. Rizzo (2008)
Applause sign in parkinsonian disorders and Huntington's disease
Laura J C Wu (2008)
Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study.
I. Le Ber (2008)
The effect of age of onset of PD on risk of dementia
D. Aarsland (2006)
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
M. Baker (2006)
The ocular motor defects in progressive supranuclear palsy
B. Troost (1977)
Eyelid movement abnormalities in progressive supranuclear palsy
Lawrence I. Golbe (1989)
Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP‐17): PPND family. A longitudinal videotape demonstration
Zbigniew K. Wszolek (2005)
Clinical phenotype of Parkinson disease dementia
J. Galvin (2006)
Progranulin null mutations in both sporadic and familial frontotemporal dementia
I. Le Ber (2007)
Alzheimer's disease and Aβ toxicity: from top to bottom
David H. Small (2001)
Alzheimer's Disease: A Central Role for Amyloid
D. Selkoe (1994)
Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With Progranulin Gene (PGRN) Mutations
K. Josephs (2007)
Alpha‐synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells
Roya Tehranian (2006)
A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series.
J. Beck (2008)
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
M. Neumann (2006)
Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families.
M. Mesulam (2007)
Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17): PPND family. A longitudinal videotape demonstration.
Z. Wszolek (2001)
Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau.
M. Spillantini (1998)
DLB and PDD boundary issues
C. Lippa (2007)
Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22.
S. Rosso (2001)
Motor signs predict poor outcomes in Alzheimer disease
N. Scarmeas (2005)
Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene
Pablo Arrisi Mercado (2005)
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.
D. Aarsland (2003)
α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells
X. Peng (2005)
A novel deletion in progranulin gene is associated with FTDP-17 and CBS
L. Benussi (2008)
Frontotemporal dementia and parkinsonism linked to chromosome 17: A consensus conference
N. Foster (1997)
Clinical diagnostic criteria for dementia associated with Parkinson's disease
M. Emre (2007)
Motor signs during the course of Alzheimer disease
N. Scarmeas (2004)
Abnormalities of optokinetic nystagmus in progressive supranuclear palsy
S. Garbutt (2004)
Clinical, imaging and electrophysiological studies of corticobasal degeneration.
Kai-Ju Huang (2007)
New and reliable MRI diagnosis for progressive supranuclear palsy.
H. Oba (2005)
Tau and neurofilaments in a family with frontotemporal dementia unlinked to chromosome 17q21–22
A. Savioz (2003)
Tau aggregation in the hippocampal formation: an ageing or a pathological process?
A. Delacourte (2002)
Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome.
M. Masellis (2006)
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
M. Hutton (1998)
This paper is referenced by
Développement de méthodes de référence pour spectrométrie de masse pour le dosage de biomarqueurs de la maladie d'Alzheimer
P. Bros (2016)
Computer-based cognitive interventions for mild cognitive impairment and dementia in older adults: protocol for a systematic review of published studies and meta-analysis
Abdullah Al Mahmud (2019)
The Role of Histone Deacetylases in Neurodegenerative Diseases and Small-Molecule Inhibitors as a Potential Therapeutic Approach
R. Bürli (2010)
Targets for AD treatment: conflicting messages from γ‐secretase inhibitors
K. Sambamurti (2011)
An approach to the patient with cognitive impairment: delirium and dementia.
J. Caplan (2010)
Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications
P. Bros (2015)
Can we improve care for patients with dementia?
J. Morley (2011)